Join Growin Stock Community!

易威1799.TW Overview

TW StockBiotech. & Medical
(No presentation for 1799)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

易威（1799）Overall Performance

易威（1799）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

易威（1799） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

易威（1799）Key Information

易威（1799）Profile

Easywell Biomedicals, Inc. develops, manufactures, and sells active pharmaceutical ingredients and over-the-counter drug products in the United States and Asia. It develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for treatment of breast cancer in PMS women; TLX-007 and TLX-004, an anti-depressant; TLX-008 for prevention of pneumocystis pneumonia; TLX-012 for treatment of epilepsy; TLX-017 for treatment of chronic angina; and TLX-011 for treatment of inflammatory lesions of rosacea. The company also develops TWB-201 for Parkinson patch; TLX-501, an urinary medicine; and TLX-502, a pneumonia medicine, as well as provides medical devices. It has a collaborative development agreement with Handa Pharmaceuticals and Handa Neuroscience, LLC for the development of TLX-050 for the treatment of neurological disorders. The company was formerly known as Actherm Inc. and changed its name to Easywell Biomedicals, Inc. in July 2015. Easywell Biomedicals, Inc. was incorporated in 1998 and is headquartered in Hsinchu City, Taiwan.

易威（1799）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
50.50%
Net Margin
-10.94%
Revenue Growth (YoY)
37.25%
Profit Growth (YoY)
18.91%
3-Year Revenue Growth
70.94%
3-Year Profit Growth
65.72%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
50.50%
Net Margin
-10.94%
Revenue Growth (YoY)
37.25%
Profit Growth (YoY)
18.91%
3-Year Revenue Growth
70.94%
3-Year Profit Growth
65.72%
default symbol

1799

易威

29.55D

-5.92%

(-0.06)

  • When is 1799's latest earnings report released?

    The most recent financial report for 易威 (1799) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1799's short-term business performance and financial health. For the latest updates on 1799's earnings releases, visit this page regularly.

  • What is the operating profit of 1799?

    According to the latest financial report, 易威 (1799) reported an Operating Profit of 7.92M with an Operating Margin of 4.54% this period, representing a decline of 13.25% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 1799's revenue growth?

    In the latest financial report, 易威 (1799) announced revenue of 174.43M, with a Year-Over-Year growth rate of -8.42%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 1799 have?

    At the end of the period, 易威 (1799) held Total Cash and Cash Equivalents of 230.74M, accounting for 0.19 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 1799 go with three margins increasing?

    In the latest report, 易威 (1799) achieved the “three margins increasing” benchmark, with a gross margin of 49.7%%, operating margin of 4.54%%, and net margin of 3.33%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1799's profit trajectory and future growth potential.

  • Is 1799's EPS continuing to grow?

    According to the past four quarterly reports, 易威 (1799)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.05. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 1799?

    易威 (1799)'s Free Cash Flow (FCF) for the period is 2.05M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 96.12% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.